Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interprotein Corporation

http://www.interprotein.com

Latest From Interprotein Corporation

Coronavirus Update: CureVac Joins mRNA Vaccines Competitors, Beijing In Lockdown Again

CureVac starts mRNA vaccine trial, Interprotein uses AI in drug discovery and South Korea's Chong Kun and Hanmi make clinical progress.

Coronavirus COVID-19 Companies

Innovation The Centerpiece In Mixed Japan 2019 Outlook

2019 has already brought one industry-shaking event in Japan with the formal completion of the Takeda-Shire deal. But how will this play out and what else can we expect in this key market over the next year?

Japan Commercial

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.

Asia Pacific Companies

Asahi deal not enough to save RaQualia from wider losses

The pharma division of the diversified Japanese chemicals and materials group Asahi Kasei has signed a collaborative research agreement with RaQualia Pharma aimed at the discovery of new therapeutics against a specific (but unidentified) ion channel target.

Gynecology & Urology Orthopedics
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
UsernamePublicRestriction

Register